CG001419
Phase 2Small molecule
CG001419 is one of 3 small molecule programs targeting Advanced or Metastatic Solid Tumour. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
2
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
4 competitors in Advanced or Metastatic Solid Tumour
#DrugCompanyPhaseTrials
1Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Phase 1
CG001419
CCullgen (Shanghai),Inc
Phase 2
Antibody-Drug Conjugates
HHellenic Cooperative Oncology Group
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CG001419. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- CCullgen (Shanghai),Inc